ISEE Stock Price
ISEE RSI Chart
ISEE Valuation
ISEE Price/Sales (Trailing)
ISEE Profitability
ISEE Fundamentals
ISEE Revenue
ISEE Earnings
Price Action
Last 7 days
1.1%
Last 30 days
4.8%
Last 90 days
44.6%
Trailing 12 Months
241.2%
ISEE Financial Health
ISEE Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ISEE
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-07-11 | Miller Christine Ann | back to issuer | - | - | -13,075 | - |
2023-07-11 | SBLENDORIO GLENN | back to issuer | - | - | -239,275 | chief executive officer |
2023-07-11 | Carroll David Francis | back to issuer | - | - | -44,152 | svp, chief financial officer |
2023-07-11 | Gibney Anthony S | back to issuer | - | - | -40,291 | evp, chief business officer |
2023-07-11 | Blumenkranz Mark S. | back to issuer | - | - | -32,088 | - |
2023-07-11 | Roberts Calvin W. | back to issuer | - | - | -47,088 | - |
2023-07-11 | Westby Keith | back to issuer | - | - | -39,652 | svp, chief operating officer |
2023-07-11 | Dugel Pravin | back to issuer | - | - | -203,035 | president |
2023-07-11 | Bolte Axel | back to issuer | - | - | -22,088 | - |
2023-07-11 | Henderson Jane | back to issuer | - | - | -22,088 | - |
Which funds bought or sold ISEE recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-11 | BLUEFIN CAPITAL MANAGEMENT, LLC | new | - | 3,733,520 | 3,733,520 | 0.71% |
2023-09-06 | Deep Track Capital, LP | sold off | -100 | -158,145,000 | - | -% |
2023-08-24 | Alberta Investment Management Corp | new | - | 2,793,140 | 2,793,140 | 0.03% |
2023-08-24 | PERCEPTIVE ADVISORS LLC | reduced | -66.4 | -5,555,880 | 6,609,120 | 0.19% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | sold off | -100 | -260,000 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 6.69 | 8,965 | 21,317 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -1.53 | 2,174,340 | 5,846,400 | 0.01% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -14.51 | 11,043,100 | 39,931,100 | 0.01% |
2023-08-15 | Blueshift Asset Management, LLC | new | - | 325,971 | 325,971 | 0.12% |
2023-08-15 | Vestcor Inc | new | - | 6,294,000 | 6,294,000 | 0.23% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of IVERIC bio
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | vivo capital ix, llc | 0% | 0 | SC 13G/A | |
| Feb 14, 2023 | deep track capital, lp | 5.88% | 7,878,119 | SC 13G/A | |
| Feb 14, 2023 | avidity partners management lp | 0.6% | 838,407 | SC 13G/A | |
| Feb 14, 2023 | rtw investments, lp | 0.6% | 821,288 | SC 13G/A | |
| Feb 14, 2023 | avoro capital advisors llc | 4.96% | 6,750,000 | SC 13G/A | |
| Feb 14, 2023 | perceptive advisors llc | 0.4% | 587,400 | SC 13G/A | |
| Feb 10, 2023 | flynn james e | 2.52% | 3,424,852 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 7.46% | 10,152,003 | SC 13G | |
| Feb 03, 2023 | state street corp | 4.66% | 6,336,836 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 7.3% | 9,751,155 | SC 13G/A |
Recent SEC filings of IVERIC bio
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Jul 21, 2023 | 15-12G | 15-12G | |
| Jul 17, 2023 | EFFECT | EFFECT | |
| Jul 13, 2023 | 4 | Insider Trading | |
| Jul 13, 2023 | 4 | Insider Trading | |
| Jul 13, 2023 | 4 | Insider Trading | |
| Jul 13, 2023 | 4 | Insider Trading | |
| Jul 13, 2023 | 4 | Insider Trading | |
| Jul 13, 2023 | 4 | Insider Trading | |
| Jul 13, 2023 | 4 | Insider Trading | |
| Jul 13, 2023 | 4 | Insider Trading |
Peers (Alternatives to IVERIC bio)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 144.1B | 26.6B | 4.58% | 21.92% | 18.06 | 5.42 | 0.75% | 21.34% |
GILD | 93.9B | 27.4B | -1.41% | 20.66% | 17.12 | 3.43 | -0.48% | 32.56% |
MRNA | 38.2B | 10.7B | -13.77% | -20.30% | 31.64 | 3.58 | -53.67% | -91.41% |
BIIB | 37.5B | 10.0B | -1.54% | 29.89% | 14.06 | 3.76 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.0B | 1.7B | 5.62% | 7.08% | 62.58 | 6.6 | 29.01% | 1345.90% |
BBIO | 4.4B | - | -4.83% | 151.82% | -7.45 | 48.33 | 54.84% | -12.96% |
DNLI | 3.1B | - | -3.06% | -19.25% | -24.06 | 37.44 | 122.90% | 54.78% |
BEAM | 1.9B | 80.2M | 7.12% | -51.65% | -5.95 | 24.27 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | 8.35% | -19.29% | -5.28 | 12.52 | -70.36% | -531.73% |
REPL | 990.8M | 15.3M | -16.17% | 7.69% | -5.45 | 64.71 | 1090.59% | -36.57% |
NVAX | 642.2M | 1.6B | -25.66% | -73.68% | -1.09 | 0.4 | 23.74% | 60.24% |
FATE | 215.8M | - | -17.67% | -90.67% | -1.02 | 1.58 | 116.83% | 16.61% |
SGMO | 141.3M | - | -10.80% | -84.01% | -0.71 | 0.59 | 113.96% | -15.19% |
VXRT | 108.1M | 2.1M | -12.90% | -67.53% | -1.07 | 52.59 | 487.70% | -8.66% |
IBIO | 4.0M | - | -8.68% | -96.58% | -0.05 | 3.21 | - | -129.46% |
IVERIC bio News
Returns for ISEE
Cumulative Returns on ISEE
-4.4%
7-Year Cumulative Returns
71.4%
5-Year Cumulative Returns
108.3%
3-Year Cumulative Returns
Risks for ISEE
What is the probability of a big loss on ISEE?
100%
Probability that IVERIC bio stock will be more than 20% underwater in next one year
88.1%
Probability that IVERIC bio stock will be more than 30% underwater in next one year.
65%
Probability that IVERIC bio stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ISEE drawdown profile look like?
Y-axis is the maximum loss one would have experienced if IVERIC bio was unfortunately bought at previous high price.
Drawdowns
Financials for IVERIC bio
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2014Q3 |
| Revenue | 14.3% | 210 | 184 | 157 | 131 | 105 | 78.00 | 52.00 | 67.00 | 82.00 | 98.00 | 113 | 128 | 143 | 158 |
| Operating Expenses | -36.1% | 102 | 159 | 205 | - | - | - | - | - | - | - | - | - | - | - |
| S&GA Expenses | -14.5% | 36.00 | 42.00 | 47.00 | - | - | - | - | - | - | - | - | - | - | - |
| R&D Expenses | -43.7% | 66.00 | 118 | 158 | - | - | - | - | - | - | - | - | - | - | - |
| Earnings Before Taxes | 90.7% | 109 | 57.00 | -192 | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | 98.7% | 114 | 57.00 | -192 | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
| Assets | -8.0% | 613 | 667 | 332 | 320 | 353 | 389 | 248 | 166 | 187 | 217 | 235 | 250 | 116 | 130 | 99.00 | 114 | 124 | 137 | 141 | 152 | 162 |
| Current Assets | -7.7% | 612 | 663 | 329 | 317 | 351 | 387 | 246 | 164 | 187 | 217 | 234 | 250 | 115 | 129 | 97.00 | 111 | 119 | 133 | 137 | 148 | 158 |
| Cash Equivalents | -1.8% | 468 | 476 | 153 | 141 | 192 | 261 | 180 | 50.00 | 29.00 | 66.00 | 123 | 246 | 108 | 126 | 95.00 | 107 | 117 | 131 | 135 | 146 | 155 |
| Net PPE | 17.2% | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Liabilities | 3.2% | 136 | 132 | 72.00 | 27.00 | 20.00 | 29.00 | 21.00 | 26.00 | 20.00 | 25.00 | 20.00 | 12.00 | 11.00 | 13.00 | 9.00 | 12.00 | 10.00 | 13.00 | 136 | 134 | 133 |
| Current Liabilities | 10.6% | 39.00 | 36.00 | 25.00 | 26.00 | 19.00 | 28.00 | 20.00 | 25.00 | 20.00 | 25.00 | 20.00 | 12.00 | 11.00 | 13.00 | 9.00 | 12.00 | 10.00 | 13.00 | 11.00 | 9.00 | 8.00 |
| LT Debt, Non Current | 0.4% | 97.00 | 97.00 | 48.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | -10.8% | 477 | 535 | 260 | 293 | 333 | 361 | 226 | 140 | 167 | 192 | 215 | 238 | 105 | 117 | 89.00 | 102 | 114 | 124 | 5.00 | 18.00 | 28.00 |
| Retained Earnings | -8.4% | -937 | -864 | -805 | -763 | -714 | -679 | -646 | -622 | -591 | -565 | -539 | -514 | -495 | -480 | -463 | -448 | -434 | -421 | -525 | -511 | -497 |
| Additional Paid-In Capital | 1.0% | 1,414 | 1,400 | 1,066 | 1,057 | 1,048 | 1,040 | 873 | 761 | 759 | 757 | 754 | 752 | 600 | 598 | 552 | 550 | 548 | 546 | 531 | 529 | 526 |
| Shares Outstanding | 0.4% | 137 | 137 | 121 | 117 | 119 | 115 | 105 | 93.00 | 93.00 | 90.00 | 93.00 | 57.00 | 53.00 | 50.00 | 42.00 | 41.00 | 41.00 | 41.00 | 36.00 | 36.00 | 36.00 |
Cashflow (Last 12 Months)
| Cashflow (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
| Cashflow From Operations | -8.0% | -176,852,000 | -163,771,000 | -136,971,000 | -122,072,000 | -106,614,000 | -98,559,000 | -97,194,000 | -85,735,000 | -78,028,000 | -66,097,000 | -56,937,000 | -54,407,000 | -51,413,000 | -48,490,000 | -46,663,000 | -45,256,000 | -44,426,000 | -41,911,000 | -45,074,000 | -50,325,000 | -72,397,000 |
| Share Based Compensation | 24.4% | 33,189,000 | 26,676,000 | 22,578,000 | 18,648,000 | 14,339,000 | 11,245,000 | 9,276,000 | 8,497,000 | 8,291,000 | 8,323,000 | 8,421,000 | 8,700,000 | 9,034,000 | 9,180,000 | 9,527,000 | 10,005,000 | 10,460,000 | 11,072,000 | 12,056,000 | 12,863,000 | 15,189,000 |
| Cashflow From Investing | 146.0% | 23,143,000 | -50,277,000 | -107,314,000 | -63,817,000 | -5,140,000 | 21,298,000 | 44,697,000 | -110,489,000 | -151,520,000 | -143,810,000 | -108,305,000 | 150,000 | 150,000 | 150,000 | 150,000 | - | - | - | - | 55,347,000 | 134,687,000 |
| Cashflow From Financing | 0.1% | 429,414,000 | 428,905,000 | 217,506,000 | 276,639,000 | 274,286,000 | 272,335,000 | 109,557,000 | 852,000 | 150,531,000 | 150,581,000 | 193,210,000 | 193,103,000 | 42,976,000 | 42,838,000 | 6,156,000 | 6,154,000 | 6,154,000 | 6,140,000 | 65,000 | 52,000 | 67,000 |
ISEE Income Statement
2023-03-31Condensed Unaudited Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
| Operating expenses: | ||
| Research and development | $ 42,083 | $ 22,557 |
| General and administrative | 31,758 | 12,113 |
| Total operating expenses | 73,841 | 34,670 |
| Loss from operations | (73,841) | (34,670) |
| Interest income, net | 3,461 | 133 |
| Other (expense) income, net | (1,849) | 1 |
| Loss before income tax benefit | (72,229) | (34,536) |
| Income tax benefit | 0 | 0 |
| Net loss | (72,229) | (34,536) |
| Comprehensive loss | $ (72,099) | $ (34,840) |
| Net loss per common share: | ||
| Basic (in usd per share) | $ (0.53) | $ (0.29) |
| Diluted (in usd per share) | $ (0.53) | $ (0.29) |
| Weighted average common shares outstanding: | ||
| Basic (in shares) | 137,087 | 118,755 |
| Diluted (in shares) | 137,087 | 118,755 |
ISEE Balance Sheet
2023-03-31Condensed Unaudited Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 467,572 | $ 476,304 |
| Available for sale securities | 132,349 | 170,531 |
| Prepaid expenses and other current assets | 11,622 | 15,991 |
| Total current assets | 611,543 | 662,826 |
| Property and equipment, net | 1,109 | 946 |
| Right-of-use asset, net | 755 | 1,182 |
| Other assets | 0 | 1,869 |
| Total assets | 613,407 | 666,823 |
| Current liabilities | ||
| Accrued research and development expenses | 20,574 | 11,555 |
| Accounts payable and accrued expenses | 18,026 | 22,843 |
| Lease liability | 774 | 1,189 |
| Total current liabilities | 39,374 | 35,587 |
| Lease liability, non-current | 0 | 11 |
| Debt, non-current | 96,987 | 96,568 |
| Total liabilities | 136,361 | 132,166 |
| Stockholders' equity | ||
| Preferred stock—$0.001 par value, 5,000,000 shares authorized, no shares issued or outstanding | 0 | 0 |
| Common stock—$0.001 par value, 200,000,000 shares authorized, 137,249,579 and 136,639,687 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 137 | 137 |
| Additional paid-in capital | 1,414,043 | 1,399,555 |
| Accumulated deficit | (937,035) | (864,806) |
| Accumulated other comprehensive income | (99) | (229) |
| Total stockholders' equity | 477,046 | 534,657 |
| Total liabilities and stockholders' equity | $ 613,407 | $ 666,823 |
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.